Tahir Amin, DipLP, co-founder and director of intellectual property of Initiative for Medicines, Access, and Knowledge, discusses the link between drug patents and innovation.
Transcript:
Do you see differences in the attitudes toward patients in the United States versus other nations?
Well that’s interesting, because largely the United States and the Europeans and Japanese have largely been the drivers of the modern intellectual property system, given particularly the United States and Europe, and then in the 80s the Japanese because they became very tech savvy and their economy grew as a result of all the technologies that they started to export.
But now as you see today, China has the highest number of applications of patents than any other country. So, I think the attitudes towards intellectual property of patents has changed, still largely driven by the philosophies of Europe and the United States, but now China is exceeding both of those in terms of number of filings.
Does that mean that China is innovating more? Probably not. I think…the number of patents equating to better innovation or higher innovation is unfortunately a myth. I think there’s a number of academic studies or ways of studying that which can disprove a lot of the statistical reasoning. I think that’s what we as an organization are trying to get to the bottom of, to say that actually just because you have more patents or just because you’re pushing more patents is going to actually enhance innovation.
We understand that people need incentives and something to secure their investments, but we think it’s a bit of a race to the bottom. Because now we’re seeing people saying, “Well only if you have more than 30,000 patent applications a year are you doing real innovation?” and I don’t think it works that way.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: Commemorating the 15th Anniversary of the BPCIA
April 8th 2025Affirming that analytical characterization is often sufficient for biosimilar approval, minimizing unnecessary clinical testing, and enhancing FDA-led education to counter stakeholder misconceptions are key recommendations put forth in this opinion piece by Sarfaraz K. Niazi, PhD.